Browsing: Taxonomy > Drug development
NICE have approved dabrafenib plus trametinib for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults.
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
The prices of cancer drugs have skyrocketed in recent years, with Pharma companies being called out by both patients and Donald Trump. Who is to blame for this increase and how can we make cancer “more affordable”?
The China National Drug Administration have granted rapid approval of Alecensa® as a monotherapy treatment for patients with ALK-positive, advanced non-small cell lung cancer.
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
Researchers have developed a quicker and more accurate way of testing new prostate cancer treatments.
The FDA has approved TIBSOVO – the first oral, targeted therapy for relapsed/ refractory acute myeloid leukemia (R/R AML) adults patients and an IDH1 mutation.
NICE have approved Alecensa for use on the NHS, following positive data from a Phase II trial, including a reduced risk of brain metastasis.